This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
Quizartinib
DrugBank Accession Number
DB12874
Background

Quizartinib is under investigation in Childhood Acute Myeloid Leukemia/Other Myeloid Malignancies. It is a potent inhibitor of FLT3.

Type
Small Molecule
Groups
Investigational
Structure
Thumb
Weight
Average: 560.67
Monoisotopic: 560.220574708
Chemical Formula
C29H32N6O4S
Synonyms
  • N-(5-(1,1-Dimethylethyl)isoxazol-3-yl)-N'-(4-(7-(2-(morpholin-4-yl)ethoxy)imidazo(2,1-b)benzothiazol-2-yl)phenyl)urea
  • Quizartinib
  • Quizartinibum
External IDs
  • AC 010220
  • AC 220
  • AC-010220
  • AC-220
  • AC010220
  • AC220

Pharmacology

Indication

Not Available

Pharmacology
Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Contraindications
Avoid life-threatening adverse drug events
Improve clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events & improve clinical decision support.
Learn more
Pharmacodynamics

In preclinical studies, Quizartinib demonstrated dose-dependent activity and favorable drug-like profiles in bioavailability, pharmacokinetics, cytochrome P450 (CYP) liability, and absorption, distribution, metabolism, excretion (ADME).

Mechanism of action

Quizartinib potently inhibits FLT3, a kinase that is mutated in approximately one-third of acute myeloid leukemia cases, and patients with FLT3 mutations are less responsive to traditional therapies.

TargetActionsOrganism
UReceptor-type tyrosine-protein kinase FLT3Not AvailableHumans
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Adverseeffects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.
Learn more
Improve decision support & research outcomes with our structured adverse effects data.
Learn more
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
Darbepoetin alfaThe risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Quizartinib.
ErythropoietinThe risk or severity of Thrombosis can be increased when Erythropoietin is combined with Quizartinib.
Methoxy polyethylene glycol-epoetin betaThe risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Quizartinib.
PeginesatideThe risk or severity of Thrombosis can be increased when Peginesatide is combined with Quizartinib.
Interactions
Identify potential medication risks
Easily compare up to 40 drugs with our drug interaction checker.
Get severity rating, description, and management advice.
Learn more
Food Interactions
Not Available

Products

Products2
Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
Product Ingredients
IngredientUNIICASInChI Key
Quizartinib dihydrochlorideWK7Q6ZIZ101132827-21-4DHYPGRVMIOATAE-UHFFFAOYSA-N

Categories

ATC Codes
L01XE52 — Quizartinib
Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as phenylimidazoles. These are polycyclic aromatic compounds containing a benzene ring linked to an imidazole ring through a CC or CN bond.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Azoles
Sub Class
Imidazoles
Direct Parent
Phenylimidazoles
Alternative Parents
N-phenylureas / Benzothiazoles / Alkyl aryl ethers / N-substituted imidazoles / Morpholines / Imidolactams / Thiazoles / Heteroaromatic compounds / Isoxazoles / Ureas
show 8 more
Substituents
1,3-benzothiazole / 4-phenylimidazole / 5-phenylimidazole / Alkyl aryl ether / Amine / Aromatic heteropolycyclic compound / Azacycle / Benzenoid / Carbonic acid derivative / Carbonyl group
show 22 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
Not Available
Affected organisms
Not Available

Chemical Identifiers

UNII
7LA4O6Q0D3
CAS number
950769-58-1
InChI Key
CVWXJKQAOSCOAB-UHFFFAOYSA-N
InChI
InChI=1S/C29H32N6O4S/c1-29(2,3)25-17-26(33-39-25)32-27(36)30-20-6-4-19(5-7-20)22-18-35-23-9-8-21(16-24(23)40-28(35)31-22)38-15-12-34-10-13-37-14-11-34/h4-9,16-18H,10-15H2,1-3H3,(H2,30,32,33,36)
IUPAC Name
3-(5-tert-butyl-1,2-oxazol-3-yl)-1-(4-{10-[2-(morpholin-4-yl)ethoxy]-7-thia-2,5-diazatricyclo[6.4.0.0²,⁶]dodeca-1(8),3,5,9,11-pentaen-4-yl}phenyl)urea
SMILES
CC(C)(C)C1=CC(NC(=O)NC2=CC=C(C=C2)C2=CN3C(SC4=C3C=CC(OCCN3CCOCC3)=C4)=N2)=NO1

References

General References
Not Available
KEGG Drug
D09955
PubChem Compound
24889392
PubChem Substance
347829030
ChemSpider
24640357
BindingDB
50300690
ChEBI
90217
ChEMBL
CHEMBL576982
ZINC
ZINC000043204002
PDBe Ligand
P30
Wikipedia
Quizartinib
PDB Entries
4rt7 / 4xuf

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
3Active Not RecruitingTreatmentAcute Myeloid Leukemia (AML) / Leukemias1
3CompletedTreatmentAcute Myeloid Leukemia (AML)1
3Not Yet RecruitingTreatmentAcute Myeloid Leukemia (AML)1
2Active Not RecruitingTreatmentAcute Myeloid Leukemia (AML) / FLT3-ITD Mutation1
2CompletedTreatmentAcute Myeloid Leukemia (AML)3
2RecruitingTreatmentAcute Myeloid Leukemia (AML)1
2RecruitingTreatmentAcute Myeloid Leukemia (AML) / Acute, recurrent Myeloid Leukemia / Blasts 20 Percent or More of Bone Marrow Nucleated Cells / High-risk Myelodysplastic Syndrome (MDS) / Recurrent Acute Biphenotypic Leukemia / Recurrent High Risk Myelodysplastic Syndrome / Refractory Acute Myelogenous Leukemia (AML) / Refractory High Risk Myelodysplastic Syndrome1
2TerminatedTreatmentAcute Myeloid Leukemia (AML)1
2, 3RecruitingTreatmentAcute Myeloid Leukemia (AML) / Myelodysplastic Syndromes (MDS)1
1CompletedTreatmentAcute Myeloid Leukemia (AML)3

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0509 mg/mLALOGPS
logP5.13ALOGPS
logP5.16ChemAxon
logS-4ALOGPS
pKa (Strongest Acidic)10.43ChemAxon
pKa (Strongest Basic)6.62ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count6ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area106.16 Å2ChemAxon
Rotatable Bond Count8ChemAxon
Refractivity168.24 m3·mol-1ChemAxon
Polarizability61.51 Å3ChemAxon
Number of Rings6ChemAxon
Bioavailability0ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Targets

Drugtargets2
Build, predict & validate machine-learning models
Use our structured and evidence-based datasets to unlock new
insights and accelerate drug research.
Learn more
Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.
Learn more
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
General Function
Vascular endothelial growth factor-activated receptor activity
Specific Function
Tyrosine-protein kinase that acts as cell-surface receptor for the cytokine FLT3LG and regulates differentiation, proliferation and survival of hematopoietic progenitor cells and of dendritic cells...
Gene Name
FLT3
Uniprot ID
P36888
Uniprot Name
Receptor-type tyrosine-protein kinase FLT3
Molecular Weight
112902.51 Da

Drug created at October 21, 2016 00:57 / Updated at February 21, 2021 18:54